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Abstract 
 
RBBP6 is an E3 Ubiquitin ligase protein with a U-box motif. It interacts with p53 
and Rb and is linked to several cellular functions. SNAMA is the Drosophila 
RBBP6 homolog, but is less characterized than its vertebrate counterparts. Gene 
expression studies on Drosophila have a potential to advance the knowledge on 
molecular mechanism underlying genotoxic stress. Previous studies have shown 
that SNAMA plays a critical role as an apoptosis suppressor and possibly in 
responses to genotoxic stress. The molecular basis for this is, however, unknown. 
Initially, two isoforms were identified by bioinformatics and one (Snama A) 
experimentally as well. Here, we confirm experimentally the existence of the 
second isoform (Snama B). We also show that these are differentially expressed 
during development and when the organism undergoes genotoxic stress. Total 
RNA samples were used to demonstrate gene expression by using Reverse 
Transcriptase Polymerase Chain Reaction. Using samples collected at different 
stages of development and from adult flies treated with the DNA damaging agent, 
irinotecan, it is shown that these isoforms are differentially expressed throughout 
development and upon genotoxic stress. This knowledge may help to understand 
the functional role SNAMA plays in normal physiology and in response to 
genotoxic stress. Furthermore, the results show that SNAMA is involved in a 
potentially beneficial intervention whereby the glycolytic pathway is bypassed by 
the addition of methyl pyruvate.  
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Quotation 
 
 
 
 
 
 
 
“The will to excel and the will to win, they endure. They are more important than 
any events that occasion them” 
- Vince Lombardi 
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1. Introduction 
1.1 The Drosophila melanogaster 
The life cycle of the Drosophila melanogaster involves four major stages; 
Embryo, Larvae, Pupae and Adult. At an optimal temperature of about 25°C, it 
takes about 12 days for the embryo to develop into an adult. 
1.1.1 The Life cycle of the Drosophila melanogaster 
At 25°C, it takes the Drosophila about 12 days to complete its life cycle, while at 
20°C it takes about 15 days as seen in figure 1.1. This indicates that the lower the 
temperature, the longer it takes for development to proceed. However, it is 
important to note that an increase in temperature may result in the death of the fly. 
After fertilization has occurred, the female fly produces embryos which later, are 
transformed into larvae, and then into pupae after three instar larval stages. 
Finally, the adult fly emerges from the pupal case. This stage is important because 
it allows the isolation of virgins. 
The Embryo 
The Drosophila melanogaster embryo is about 0.4 mm in length. It has a pair of 
filaments called micropyles that protrude from its dorsal surface. This pair of 
filaments functions to transfer the sperm into the ovum during fertilization. The 
female requires just one mating process from which it can store many sperm cells. 
After the sperm enters the female and makes contact with the egg via a tiny 
opening located at the anterior ending, meiosis occurs and this result in the 
formation of the egg nucleus. The egg and sperm nuclei join side by side to form 
the zygotic nucleus in the embryo. 
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Figure 1.1: Life cycle of Drosophila melanogaster. 1 day after the egg is fertilized, the 
larva hatches. First, second, and third instar are the different larval stages after which the 
pupae emerges. During the pupae stage most of the larval tissues are removed, shortly 
after adults emerge. Duration of time is given at 25°C. 
 Source: Adapted from (Wolpert et al 1998) 
The Larva 
The larvae develop in three stages (called instars); the 1
st
 instar, 2
nd
 instar and 3
rd
 
instar. They can grow up to 4.5 mm in length by the 3
rd
 instar. A male larva can 
be differentiated from its female counterpart by the size of its gonad. The testis of 
a male is much larger than the ovary. This is readily distinguishable by the naked 
eyes without dissecting the larva. 
The Pupa 
After the 3
rd
 instar, the larva begins to slowly crawl to a dry surface (normally the 
side of the vial or bottle). During the process of pupation the white larva turns into 
a dark brown case and becomes harden. The entire process takes about 2 days. 
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Adults 
Four (4) days after pupation the adults emerge. An adult fly can either be male or 
female and they can be distinguished in several ways (Table 1.1). 
 
Table 1.1: Distinguishable characteristics of the male and female Drosophila 
melanogaster 
FEATURES ADULT MALE ADULT FEMALE 
Size Much smaller than the 
female. 
Bigger in size than the 
male. 
Tip of the abdomen Not elongated. Elongated. 
Abdominal markings Darker Markings. Lighter markings. 
Abdominal segments  5 segments 7 segments 
  
1.1.2 Drosophila embryonic development and axis formation  
During early development, several genes are expressed by the female and 
deposited at specific positions in the embryo. These genes are called “maternal 
effect” genes as the phenotype of the offspring is dependent on the genotype of 
the female (mother) regardless of the male genotype. At the cellular blastoderm 
stage the embryo expresses zygotic genes, to continue embryonic development.  
Maternal effect genes are critical in forming the two axes (the antero-posterior 
axis and the dorso-lateral axis) within the embryos. The products of these 
maternal effect genes define the correct establishment of axes by spatially 
distributed RNA and proteins (figure 1.2). Zygotic genes in the nuclei are then 
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activated by these proteins in preparation for the next round of patterning; 
segment formation. 
Maternal effect genes that specify the antero-posterior axis 
Prior to fertilization of the egg, differences in the egg are created along the antero-
posterior axis by the expression of maternal effect genes. The future anterior head 
and posterior ends of the fly are distinguished by these differences. However, 
these mutations strongly effect the development of the offspring. Four maternal 
effect genes (bicoid, hunchback, nanos and caudal) are dispersed along the 
antero-posterior axis and are critical in endowing it (St Johnston and Nusslein-
Volhard, 1992).  
 Four classes of these maternal effect genes exist; 
1. Those affecting the anterior region: For example, loss of function 
mutations in maternal bicoid, lead to loss of structures in the head and 
thoracic regions. In some cases, these structures can be substituted with 
structures from the posterior regions. 
2. Those affecting the posterior regions: Mutations in nanos , lead to an 
absence of abdominal region structures resulting in smaller abnormally 
sized embryos. 
3. Those affecting both terminal regions: Mutations in torso has serious 
effects to the acron and telson located at the head and tail sections of the 
embryo resulting to interference in the developmental process of the fly. 
4. Those affecting the dorso-ventral regions: Mutations in toll, results in 
defects during embryogenesis. 
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Figure 1.2: Summary of the critical steps of all maternal pathways (Anterior, 
posterior, terminal and dorso- ventral pathways). The location of Gene X, Gene Y and 
genes showed in parenthesis are speculative. 
Source: Adapted from (St Johnston and Nusslein-Volhard, 1992). 
 
The bicoid gene establishes the antero-posterior axis 
Before fertilization of the egg, the bicoid mRNA can be found at the anterior end. 
After fertilization, translation occurs and the protein moves from the anterior end 
to the posterior end forming an antero-posterior concentration gradient. Based on 
the formation of this gradient, positional information necessary for future 
patterning is obtained. The bicoid protein functions as a morphogen by turning on 
specific zygotic genes at differing concentrations thereby begin a fresh pattern of 
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expressed genes along the antero-posterior axis. Thus, the bicoid is a crucial 
maternal effect gene involved in the early stages of development. 
Nanos and Caudal proteins control posterior patterning. 
The posterior end is controlled by nine maternal effect genes. These genes are 
responsible for the localization of distinct maternal factors within the oocyte. 
Amongst them is oskar, which functions in localizing the nanos mRNA at the 
posterior end of the unfertilized egg. A deficiency in nanos results in the absence 
of abdominal regions. The nanos protein is responsible for the suppression of 
another maternal effect gene called hunchback. This suppression is crucial 
because the hunchback is also zygotically expressed and controls the 
establishment of the bicoid gradient. During early embryogenesis, hunchback 
becomes activated by elevated concentrations of the bicoid protein at the anterior 
of the embryo. This results in the formation of an antero-posterior gradient of the 
hunchback protein.  But since hunchback is also maternally expressed at the 
posterior end, a very high concentration of the hunchback protein is observed at 
that end. Therefore, for a distinct antero-posterior gradient to be observed nanos 
has to inhibit its own expression at the posterior end by binding to the hunchback 
mRNA (Rivera-Pomar et al., 1995). 
Another important maternal product, caudal, is expressed ubiquitously within the 
embryo. The bicoid protein inhibits the caudal protein leading to the formation of 
a posterior to anterior gradient. At the posterior end, the concentration of the 
caudal protein is highest because of the low concentration of its inhibitor; the 
bicoid protein. When the caudal gene is mutated it results in some abdominal 
segments being abnormally developed (Struhl, 1989). 
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1.2 The p53 pathway during DNA damage 
 Structural and Functional Characteristics of p53 
p53 plays a very important role in, protecting genome integrity, cell cycle 
regulation and apoptosis. Mutation in p53 occurs in many human cancers (Levine, 
1997). Tp53 (Human p53) is made up of 393 amino acids and is divided into four 
domains (Zhu, 2000). These domains each have their own unique functions. At 
the N-terminus is the transactivation domain which is composed of 42 amino 
acids. Within this domain is a region (amino acids 13-29) that interacts with 
Mdm2 protein (Kussie et al., 1996). The DNA binding domain is found between 
amino acids 94-292 and it possesses the ability to fold into a β-sheet sandwich 
thereby forming a scaffold for a large loop and a helix motif which has a direct 
interaction with DNA. The majority of the missense mutations that occur in p53 
leading to cancers occur within this region (Levine, 1997). These missense 
mutations alter the amino acids that interact and bind with DNA or which are 
responsible for maintaining the three-dimensional structure of p53. Mutated p53 is 
defective in binding DNA therefore cannot undergo transactivation. At the C-
terminus of p53 is the tetramerization domain composed of amino acid 324-355 
and is responsible for the oligomerization of p53 subunits (Jeffrey et al., 1995). 
p53 is functional as a tetramer (Jin et al., 2000). 
1.2.1 p53 induces apoptosis. 
Under normal physiological conditions, the p53 levels are kept very low by its 
short half-life and by downregulation induced by proteins such as Mdm2, cop1 or 
pirh2. These proteins induce p53 degradation via the ubiquitin/proteasome 
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pathway. When the cell becomes stressed due to hypoxia, damage to the DNA, or 
when oncogenes are activated abnormally, signals are sent to p53 to stabilize it. 
The level of p53 increases rapidly and becomes active to function as a 
transcriptional factor. This activation of target genes located downstream like 
cyclin G, Bax and p21 appears to be responsible for the mechanism through which 
cell cycle progression and apoptosis are regulated by p53 (Jin et al., 2000). 
1.2.2 Regulation of p53 
In normal healthy cells, p53 is tightly regulated causing it to be present in very 
low amounts due to the fact that the protein is very quickly degraded after its been 
synthesized (Kubbutat et al., 1997). Regulation of p53 stability ensures that its 
levels are well under control. One of the major mechanisms by which low p53 
levels are maintained is by ubiquitination and subsequent degradation in the 
proteasome. This mechanism involves a group of enzymes that join several 
ubiquitin chains to lysine residues in the protein of interest (Varshavsky, 1997). 
The joining of ubiquitin to proteins for degradation requires the activities of; 
Ubiquitin-activating enzyme (e1), Ubiquitin-conjugating enzyme (e2) and the 
Ubiquitin-ligase (e3). 
Degradation of p53 and Mdm2 
Mdm2 is a critical component in the pathway leading to the degradation of p53. 
Its expression is upregulated when a p53 response is activated , although unlike  
other p53 targets there is no proof that it controls any effects of p53 downstream 
such as apoptosis or cell cycle arrest (Marston et al., 1994). The major role of 
Mdm2 is to directly bind p53 thereby inhibiting its activity. Mdm2 binds to the 
transactivation domain of p53 at the N-terminus. This interaction alone can inhibit 
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the function of p53 by decreasing its ability to stimulate gene expression. In vitro 
studies have shown that Mdm2 can also function in the degradation of p53 by 
functioning as an E3 ubiquitin-ligase (Honda et al., 1997). E3 ubiquitin-ligases 
possess the RING (Really Interesting New Gene) finger domain and function by 
attracting ubiquitin to the protein that is to be degraded; this then leads to the 
degradation of the protein in the proteasome. Significantly, Mdm2 not only targets 
p53 for degradation but also auto-ubiquitinates, therefore it likely regulates itself 
(Honda and Yasuda, 1999). Regulation of p53 by Mdm2 is very crucial in normal 
development, since deficiency in Mdm2 results in early embryonic lethality 
(Jones et al., 1995). This lethality is rescued by the deletion of p53 and this 
supports the theory that a loss of Mdm2 activity leads to an increase in the activity 
of p53. The importance of the Mdm2/p53 pathway can be further illustrated by 
cancerous cells expressing the inactive form of p53. Mutant p53 lose their tumour 
suppressing abilities and become unable to activate the expression of Mdm2. 
Consequently mutant p53 are stable and accumulate to large amounts within the 
cell (Kubbutat et al., 1997).  
In Drosophila, Mdm2 is absent but it is hypothesized that SNAMA might have 
similar functions. This hypothesis was drawn from the fact that SNAMA 
possesses the RING finger domain, which has the E3 ubiquitin-ligase activity. 
Also, like Mdm2, SNAMA possesses potential binding sites for p53 and Rb. 
(Mather et al., 2005).  
Stabilization of p53  
The degradation of p53 in normal cells is essential to reduce p53 activity. Since it 
has been observed that the degradation of p53 is mostly regulated by Mdm2, the 
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stabilization of p53 will be largely dependent on mechanisms that inhibit the 
binding of Mdm2 to p53. The stabilization of p53 is a critical response to different 
forms of stress within the cell. When p53 is activated and cell growth inhibited in 
response to stress, it prevents the progression and development of tumour cells by 
causing an inhibition of  the proliferation of abnormal cells (Levine, 1997).  
One of the most common ways to inhibit interaction between Mdm2 and p53 is by 
the modification of either of the two proteins. p53 undergoes modification by 
phosphorylation at various sites after DNA damage (Meek, 1998) and various 
kinases are involved in this process. In vitro experiments have shown that several 
kinases (ATM,JNK,DNA-PK,ATR and CK1) are involved in the phosphorylation 
of residues at the N terminus of p53 (Jayaraman and Prives, 1999). Evidence has 
shown that ATR  and ATM phosphorylates serine15 in vivo (Khanna et al., 1998) 
and PKR phosphorylates serine18 in mouse p53 (Cuddihy et al., 1999). 
Phosphorylation at the N-terminus of p53 correlates with its stabilization, 
although it has been observed that different patterns of phosphorylation occur in 
response to varying stress signals indicating that no single site is liable for the 
stabilization of p53 (Ashcroft and Rorsman, 1989). Mdm2 can also undergo 
phosphorylation (Mayo et al., 1997).  
1.3 Impact of p53 in energy metabolism: Glycolysis and oxidative 
phosphorylation 
In the regulation of energy metabolism, p53 interposes at different points in the 
glycolytic and oxidative phosphorylation pathways (Figure 1.3). One major way 
in which p53 functions is by slowing down glycolysis and enhancing oxidative 
phosphorylation. Through transcriptionally regulating target genes, p53 balances 
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the use of both pathways and this may provide a way in which tumouregenesis 
can be blocked (Puzio-Kuter, 2011).  
Metabolic pathways are influenced by p53 because of the ability of p53 to 
regulate the expression levels of genes that affect metabolic products. For 
example, p53 elevates the expression levels of SCO2 (cytochrome c oxidase 2), 
PUMA (the p53 modulator of apoptosis), GLS2 (glutaminase 2), GLUT1 
(Glucose transporter 1), GLUT4 (Glucose transporter 4), TIGAR (Tp53-induced 
glycolysis and apoptosis regulator) and p53 reduces the expression of PGM 
(Phosphoglycerate mutase) (Schwartzenberg-Bar-Yoseph et al., 2004). The 
induction of TIGAR by p53,  leads to the reduction of fructose-2,6-bisphosphate 
lowering  glycolysis (Bensaad and Vousden, 2007). When glycolysis is decreased, 
the pentose phosphate pathway is activated and resulting in limiting of cell death 
induced by oxidative stress. Glycolysis is also reduced when PGM expression is 
reduced by p53. Increasing PGM results in an increase in glycolytic flux and 
excessive proliferation, this occurs in certain cancers possessing mutant p53 
(Kondoh et al., 2005). p53 also functions in regulating the expression of GLUT1 
and GLUT4 by repressing these genes (Schwartzenberg-Bar-Yoseph et al., 2004). 
Mutant p53 cannot repress the expression of GLUT1 and GLUT4, allowing for 
the supply of energy to the cell and an increase in glucose metabolism. 
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Figure 1.3: Role of P53 and HIF(Hypoxia-inducible transcriptional factor) in the 
regulation of metabolic pathways. p53 regulates the expression of critical components 
of the glycolytic pathway (in the cytosol) and TCA pathway (in the mitochondria). 
Source: Adapted from  (Johnson and Perkins, 2012). 
 
1.4 Methyl pyruvate, is an essential component of glycolysis 
Production of ATP in the mitochondria is a very crucial step in stimulus-secretion 
coupling. This coupling is glucose-induced and it occurs in the beta cells of the 
pancreas (Duchen, Smith et al. 1993). When ATP/ADP levels are elevated, it 
results in KATP channels closure, depolarization and the opening of Ca
2+
 channels, 
the influx of Ca
2+
 and finally secretion of insulin (Ashcroft and Rorsman, 1989). 
Pyruvate metabolism in the citrate cycle produce reduction equivalents for the 
production of ATP in the mitochondria (Maechler and Wollheim, 1999). Pyruvate 
is the major intermediate of glycolysis in the metabolism of glucose but does not 
in fact play a role as a primary stimulus for the secretion of insulin in β-cell of the 
13 
 
pancreas. However, various studies show that methyl pyruvate is a cogent 
stimulator of the secretion of insulin (Dukes et al., 1998). The lipophillic 
properties of methyl pyruvate enable it to accumulate within the mitochondria. 
Studies with Drosophila have tested the effects of methyl pyruvate in food fed to 
flies. Adult flies were treated with a combined treatment with camptothecin and 
10% methyl pyruvate for three days and then left to recover for another nine days 
and it was observed that although this treatment was observed to be toxic to the 
flies, there was also an increase in the number of eggs that developed into larvae 
compared to eggs produced by camptothecin treated flies (Hull and Ntwasa, 
2010). This observation indicates that methyl pyruvate might have a positive 
effect in development of flies but is toxic to the adult fly at 10% concentration. It 
is therefore necessary to investigate the effects of methyl pyruvate at varying 
concentrations as this might produce interesting results.                                          
1.5 Drosophila p53 
The Drosophila homologue is encoded by a lone gene that is structurally similar 
to the human family members including Tp53, Tp63 and Tp73. Structurally, both 
Tp53 and Dmp53 contain 2 promoters; the first located upstream in the regulatory 
region and the second in the first intron. 
Transcriptional activity of Dmp53 
In most cases, Tp53 functions as a transcriptional factor by binding to DNA with 
the specific DNA binding domain. When p53 binds DNA, it represses or induces 
target genes to control particular cell responses. Transcriptional activity of Tp53 
determines the process by which the cell responds to genotoxic stress (Beckerman 
and Prives, 2010). Dmp53 possesses a DNA binding domain identical to that 
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found in Tp53 and the transcriptional activity of Dmp53 has been shown (Brodsky 
et al., 2000). 
Dmp53 is expressed during development.    
Maternal RNA Dmp53 is transferred to eggs in abundant quantities and its levels 
in the embryo remain elevated until cellularization of the blastoderm. In the 
oocyte, Dmp53 is expressed ubiquitously, however, during the mid- stage of 
embryogenesis RNA distribution becomes more prominent in certain positions 
such as the mesoderm but low in the neural and epidermal layers (Ollmann et al., 
2000).   
Regulation of Dmp53 
In the regulation of Dmp53, dRad6 plays a very critical role. dRad6 is the 
Drosophila homolog of Rad6 (Chen et al., 2011). Rad6 is an E2 enzyme 
(ubiquitin-conjugating enzyme) involved in the repair of DNA damage and in the 
regulation of gene transcription by catalyzing of the ubiquitination of specific 
target proteins in mammalian cells and yeast (Kim et al., 2009; Koken et al., 
1991). Reduction of dRad6 increases the amounts of Dmp53 which in turn causes 
the degradation of dRad6. dRad6 interacts with Dmp53 by binding to its 
transcriptional domain thereby regulating the ubiquitination of Dmp53. A loss of 
function in dRad6 results in lethal consequences and morphological changes in 
adult flies (Chen et al., 2011). 
Role of Dmp53 in apoptosis 
During DNA damage, for example one caused by radiation, Dmp53 is activated 
resulting in the activation of ATM kinase located in the mei-41 locus. Dmp53 
then interacts and binds to enhancer element (which is radiation specific) and 
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activates its transcription. Consequently, the Reaper protein binds DIAP1 
(Drosophila inhibitor of apoptosis protein) and blocks it from inhibiting caspase 
cascade activation. ICAD (inhibitor of caspase deoxyribonuclease) is then cleaved 
to give free CAD by caspase 3, resulting in apoptosis (Steller, 2000).  
Role of reaper-Family proteins in the induction of apoptosis 
The Reaper-family proteins namely grim, hid (head involution defective) and 
reaper play a critical role in inducing apoptosis (Kornbluth and White, 2005). The 
absence of all these genes results in the complete blocking of apoptosis (White et 
al., 1994) while their expression leads to the induction of apoptosis (Grether et al., 
1995). Proteins encoded by these genes contain a short motif located at the N-
terminus called the IAP-Binding-Motif (IBM), which is essential for IAP-binding 
and apoptosis (Shi, 2002). Reaper-family proteins use their IBM to bind a unique 
domain present in IAPs ( inhibitor of apoptosis proteins) called BIR (Baculovirus 
inhibitory repeat) (Kornbluth and White, 2005), and this interaction prevents IAPs 
from inhibiting caspases (cysteine-aspartate proteases that play a huge role in 
apoptosis) (Salvesen and Duckett, 2002). Reaper can also promotes the auto-
ubiquitination and subsequent degradation of IAPs (Ryoo et al., 2002). 
1.6 SNAMA, the Drosophila homologue of RBBP6 
SNAMA (Something that sticks like glue) is a protein with 1231 amino acids. It 
has a conserved DWNN (Domain With No Name) made up of 76 amino acid 
residues, a Zinc finger domain of a CCHC kind, a RING finger domain, a lysine 
rich domain and a NLS (Nuclear localisation signal) (Mather et al., 2005). Its 
domain structures indicate that it might play a crucial role within the cell and may 
act in apoptosis and RNA processing. Previous studies have also indicated that 
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there might be an interaction between SNAMA and Dmp53, in which SNAMA 
might act as a suppressor of apoptosis or in negatively regulating activators of 
apoptosis. SNAMA possesses the DWNN domain (which is ubiquitin-like) and a 
RING finger domain and this suggests that it could be an UDP (Ubiquitin domain 
protein) and have an E3 ligase activity (Mather, 2006). Two Isoforms of Snama 
exists; Snama A and Snama B. Snama A possess 10 exons (3 more than Snama B). 
DWNN domain 
The 3-dimensional structure of this domain is identical to that of ubiquitin. The 
primary structure of the DWNN domain is, however, 22% similar to ubiquitin 
(Mather et al., 2005). The resemblance of the DWNN domain to ubiquitin might 
stipulate that RBBP6 acts via ubiquitin modification. DWNN is unique to the 
RBBP6 family only and is located at the N-terminus of the orthologues (Pugh et 
al., 2006).  
ZINC finger domain 
They make up an important group of factors that play a role in gene expression 
and transcription. The Zinc finger motifs are the most occurring motifs found in 
eukaryotic proteins (Jantz et al., 2004). They are rich in cysteine and histidine and 
found in a variety of proteins with one of their most important characteristic being 
their binding with zinc ions. In the Drosophila, almost all zinc fingers play critical 
roles in some developmental processes and also in protein-protein synergy (Hart 
et al., 1996). They also orchestrate the way in which DNA, RNA and proteins 
interact with each other. The most frequently occurring zinc finger motif is the 
CCHH (Miller et al., 1985). 
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Cysteine-rich domain 
SNAMA possesses a cysteine-rich domain that is very similar to a RING finger. A 
RING finger can be defined as a zinc finger that has been altered (Freemont et al., 
1991). The amino acid histidine, located at position 4 is unique to RING finger 
motifs but in the cysteine-rich domain, it is replaced by the amino acid, serine. 
However, this domain is often considered as “RING finger-like”  because the 
RING finger domains usually possesses ubiquitin-ligase activity that allows the 
SNAMA protein to function in adequately altering other proteins. In SNAMA, 
ubiquitin-ligase activity has not been shown but it undoubtedly contains a 
cysteine-rich region (Mather et al., 2005).   
Snama-p53 interaction; a role in Apoptosis 
SNAMA has been shown to play a role during apoptosis and in the development 
of embryos (Mather et al., 2005). The DWNN domain in SNAMA includes a 
region that has striking structural resemblance to PACT. PACT (the mouse 
homologue of RBBP6) is a murine polypeptide that has the ability to bind non-
mutated p53 subsequently disrupting p53-DNA specific binding (Simons et al., 
1997). The PACT protein has been identified to be involved during cell damage or 
stress by its binding to p53 (Sakai et al., 1995) which implicates its role in 
apoptosis. Apoptosis is programmed cell death and occurs in all organisms that 
are multicellular. Apoptosis controls the proliferation of normal and damaged 
cells. SNAMA appears to function with p53 during apoptosis (Mather et al., 
2005). p53 suppresses tumours by inducing apoptosis and it is well known that  
mutations in p53 occurs in more than half of all human cancers.  
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SNAMA is expressed during development  
SNAMA is expressed as a 4.6kb throughout development and it is expressed (in 
varying amounts) at every stage of the development of the Drosophila by being 
expressed in high amounts at the early stages of development and in lower 
amounts in adults (Mather et al., 2005). 
1.7 Camptothecin, a DNA damaging agent 
Camptothecin (CPT) and its analogues are extensively used to treat several 
cancers including ovarian and colorectal cancers. These drugs target cells that are 
rapidly dividing causing strand breaks during replication resulting in apoptosis 
(Liu et al., 2000). CPT analogues like Irinotecan have improved pharmacokinetic 
properties and are preferred to CPT, for instance irinotecan is water-soluble and is 
a better CPT- derivative (Schulz et al., 2009). These structural analogues had to be 
developed because of the high toxicity and poor solubility of CPT. CPT and its 
structural analogues are topoisomerase poisons that function by inhibiting DNA 
topoisomerase 1 (Topo1). Topo1 is an enzyme located within the nucleus and it 
introduces temporary breaks that are single-stranded on the DNA, thereby 
relieving positive supercoils during the process of replication. Topo1 re-joins 
nicked strands to form unaltered DNA.  A crucial step in this process is forming a 
complex (which is capable of being split) between the DNA and the Topo1 via a 
covalent bond between the 3’end of the strand of DNA and an amino acid 
(tyrosine) at the active site of the enzyme. Topo1 is a critical enzyme during 
Drosophila embryonic development and is found mainly within the ovaries (Lee 
et al., 1993).  CPT and its analogues transform Topo1 into poison by ensuring the 
cleavable complex is stable for preventing re-ligation of the nicked strands. This 
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stabilization results in double-strand breaks during DNA replication 
compromising the genome. Topo1 is the only target of CPT (Hsiang et al., 1985). 
This allows us to target specific pathways. However, since replication occurs in 
all cells albeit at higher rate in dividing cells, this specificity is somewhat reduced.  
Consequently, while CPT drugs act against cancer cells, they also have an adverse 
effect on normal cells. Irinotecan, which is a CPT derivative, can induce 
programmed cell death in a manner that is p53 dependent (Takeba et al., 2007). 
1.8 Aim. 
The main aim of this study is to define temporal expression patterns of Dmp53 
and SNAMA during development and during response to genotoxic stress in order 
to understand their biological functions. 
1.9 Objectives. 
1. Total RNA Extraction.  
2. Temporal expression patterns of snama isoforms using RT-PCR. 
3. Differential expression patterns of snama isoforms and Dmp53 when 
treated with a camptothecin derivative; irinotecan. 
4. The effects of bypassing glycolysis during and after treatment with 
irinotecan.
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2. Materials and Methods 
2.1 Materials. 
2.1.1 Media 
Table 2.1: Media used in the duration of this study 
MEDIA COMPOSITION 
Apple juice agar 2% agar; 1.25% sucrose; 0.025% streptomycin; 0.15% 
methylparaben and 24-25% apple juice(v/v) 
 
LB medium 
 
1% NaCl; 1% tryptone; and 0.5% yeast extract 
  
LB agar 
 
LB medium and 1.5% agar 
 
LB/XGAL/IPTG plates 
 
LB medium; 1.5% agar; 0.2 mM IPTG; and 40 µg/ml X-
gal 
 
LB/Ampicillin medium  
 
LB medium and 50 µg Ampicillin 
 
LB/Ampicillin plates 
 
LB medium; 1.5% agar; and 50 µg Ampicillin 
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2.1.2 Solutions and buffers. 
Table 2.2: Molecular biology solutions and buffers 
SOLUTIONS/BUFFERS  COMPOSITION 
 
10X MOPS buffer 
 
50 mM Sodium Acetate; 10 mM EDTA (pH 7); and 0.25 
MOPS. To be stored in the dark 
 
0.5M Na2EDTA (pH 8.0) 
 
186.12 g Na2 EDTA-2H2O 
 
0.1M IPTG- 50 ml 
 
1.19 g 1PTG 
 
Xgal (20 mg/ml)- 20 ml 
 
400 mg X-gal; and 20 ml N, N’-dimethyl formamide. 
Ethanol Acetate (1:25) 1 ml Ethanol; 25 ml Acetate. 
 
10X PBS- 1 litre 
 
80 g NaCl; 2 g KCl; 26.8 g Na2HPO4-7H2O; and 
KH2PO4. 
 
50X TAE- 1 litre 
 
2 M Tris-base; 5.7% Glacial acetic acid; and 0.5 M 
EDTA. 
 
RNA Loading Buffer 
 
DEPC-treated water; 50% glycerol; 1 mM Na2EDTA; 
and 0.4% Bromophenol Blue. 
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RNA Sample buffer 
 
10 ml deionized formamide; 2.5 ml 37% formaldehyde 
and 2 ml 5X MOPS. 
 
DEPC- treated water 
 
0.1- 0.2 ml DEPC; and Water. 
 
2.1.3 Oligonucleotides (primers) 
All the Oligonucleotides used were purchased from Inqaba-Biotec, produced by 
Thermo-Scientific. 
Table 2.3: Oligonucleotides and their Sequences used in this study 
PRIMER SEQUENCE 
Dmp53 Fwd 5ʹ CAATCCGTGCTGCGCGAAAT 3ʹ 
Dmp53 Rev 5ʹ CCCACAGATGCAACAGATTTC 3ʹ 
Snama A Fwd 5ʹ ATCTGGACATCGTCGCTCTG 3ʹ 
Snama A Rev 5ʹ CTTCTTCTGGCGATCCCCT 3ʹ 
Snama B Fwd 5ʹ GATGCCTTGCAATCCTCAGC 3ʹ 
Snama B Rev 5ʹ CAAAGTATGCCGAATATAGATTC 3ʹ 
RP49 Fwd 5ʹ TGTTGTGTCCTTCCAGCTTCAA 3ʹ 
RP49 Rev 5ʹ ACTGATATCCATCCATCCAGATAATG 3ʹ 
AB fwdexon3 Snama 5ʹ TGAGGAATTCGGTGAACG 3ʹ 
Brevutr Snama 5ʹ ATCCACATGGTAGCGGGAT 3ʹ 
Arevexon7 Snama 5ʹ CAACGGATCGTCAATGG 3ʹ 
DREF Fwd 5ʹ TGAGAGTGCATTTGAAGCAT 3ʹ 
DREF Rev 5ʹ TTGGTCAGCACCTTGTGA 3ʹ 
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Reaper Fwd 5ʹAAACCAGAATTCATGGCAGTGGCATTCTAC3ʹ 
Reaper Rev 5ʹTTACTCGAGCTCTCATTGCGATGGCTTGCG3ʹ 
 
2.1.4 Chemicals and kits 
Table 2.4: Chemicals /Kits used and their manufacturers 
CHEMICALS/KITS MANUFACTURER with catalogue 
                    Number 
Chloroform (99+ %) 
 
Sigma- Aldrich 
C-2432-500 ml 
EDTA 
 
United States Biochemical 
CAT 15698 
Nuclease free water 
 
Qiagen 
CAT 129117 
2-Propanol 
 
Merck 
1036573 
Dimethyl Sulfoxide 
 
Sigma-Aldrich 
D8418- 100 ml 
Glycerol 
 
Saarchem 
1025192 
Acetic acid 
 
Saarchem 
10274367 
MOPS 
 
Sigma 
M1254- 250 G 
Methyl Paraben 
 
Sigma 
H5501- 100G 
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Agarose powder Seakem 
5004- 500 g 
Plasmid plus maxi kit (25) Qiagen 
12963 
RevertAid first strand cDNA 
synthesis kit 
 
Thermoscientific 
#K1622 
PCR mastermix(2X) 
 
ThermoScientific 
#K0171 
PGEM®-T Easy vector 
system 
 
Promega 
A3610 
E cloni 10G and 10GF 
chemically competent cells 
Lucigen 
60106- 1 
Irinotecan hydrochloride 
 
Sigma 
L1406- 50 mg 
Ampicillin Sodium salt 
 
Sigma 
A29518 - 25 G 
Streptomycin sulfate salt 
 
Sigma 
56501-50 G 
Tri Reagent 
 
Sigma 
BCBF12310 
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2.1.5 Laboratory equipments used 
Table 2.5: Laboratory Equipment/Machinery used in this study 
EQUIPMENT MANUFACTURER 
 with Model Number 
Microwave Oven 
 
KIC 
MWS- 900M 
Hot plate/Magnetic stirrer Freed Electric 
MH4-9517 
Digital dry bath 
 
Labnet 
D1100-2300 
GeneAmp PCR System 
 
Perkin Elmer 
2400 
Biofuge  
 
Heraeus Instruments 
D-31520 
Microscope 
 
Olympus 
SZ40 
Weighing balance 
 
Precisa 
XT220A 
Gel doc System 
 
Bio-Rad 
XR
+
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2.1.6 Molecular Biology Enzymes 
Table 2.6: Molecular biology enzymes used and Manufaturers 
ENZYME MANUFACTURER 
NdeI New England Biolabs (NEB) 
NcoI New England Biolabs (NEB) 
SalI New England Biolabs (NEB) 
AatII Fermentas 
PstI Fermentas 
PvuII Promega 
HinfI Promega 
EcoRI New England Biolabs (NEB) 
 
2.2 Methods 
2.2.1 Fly maintenance, treatment and stocks 
Wild type Canton S flies were placed in vials containing cornmeal agar plus yeast 
and reared at 25
°
C.  Flies were transferred to new vials on a weekly basis to 
maintain healthy fly stocks. Flies were exposed to different dozes of combination 
of methyl pyruvate and irinotecan by making a mixture of these chemicals in 
yeast blobs. Duration of exposure was 3 days after which they were transferred to 
fresh vials containing untreated yeast blobs and left to recover for a period of 3- 9 
days depending on the experiment to be performed.  
Drosophila stocks 
The Snama and p53 genes were both simultaneously knocked out in wild type 
Canton S flies producing p53
-/-
/Snama
-/-
 mutant flies. The mutant flies were a kind 
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gift from Professor Jean-Marc Reichhart in Strasbourg niversity, France. The 
mutant phenotype observed possessed curly wings and red eyes. 
 
 
 
Figure 2.1: An example of a vial (A), bottle (B) and a cage (C) respectively, used in 
rearing flies. The cage is used to rear large amounts of flies and is effectively used in the 
collection of embryos. 
 
2.2.2 Collection of developmental stages of the flies 
Embryos were collected with apple juice agar plates attached to carefully labelled 
cages. Adult flies were put in these cages and embryos collected within the 
specific time periods. Larvae and Pupae were collected by setting up larval boxes. 
Adult males and females of the same age were collected directly from either vials 
or bottles.  
2.2.3 RNA Extraction  
RNA extraction was done based on the guanidinium method of (Chomczynski, 
1993) using the TRIzol
®
LS reagent. Embryos/Larvae/Pupae/Adult flies were 
A B C 
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collected and transferred to 1.5 ml eppendorf tubes. 500 µl of TRIzol was then 
added and a plastic homogeniser used to homogenise the samples. The sample 
was vortexed and 200 µl of chloroform was added. Sample was then centrifuged 
at 13,000 g at 4°C. Supernatant was collected and 200 µl of isopropanol and 
centrifuged at 13,000 g at 4°C. Pellet was collected and washed with very cold 
ethanol (75 µl). Ethanol was then removed and pellet left to air dry. The pellet 
was dissolved in 50 µl of RNase free water. The samples were then heated in a 
dry bath at 65°C for about 10 mins and then placed on ice immediately. 
Concentration of the RNA samples was determined by use of the Nanodrop®. 
 
2.2.4 Reverse Transcriptase Polymerase Chain Reaction 
CDNA Synthesis 
A reaction tube was placed on ice and about 5 µg of RNA was placed into the 
tube. 1 µl of Oligo (dT) primer was added and Nuclease free water was also added 
to make up 12 µl. 1 µl each of Rnase inhibitor (Ribolock) and Revertaid reverse 
transcriptase was placed in the tube followed by 4 µl of the reaction buffer and 
2µl of the 10 mM DNTP mix. Samples were then incubated for 60 mins at 42°C 
and the reaction terminated by heating at 70°C for 5 mins. 
Polymerase Chain Reaction 
RT-PCR was performed based on the protocol provided on the PCR Mastermix 
booklet #K1071. All reagents were added onto a PCR tube standing on ice. After 
all the reagents have been properly added, the tubes were placed onto the PCR 
machine. Below is an example of a PCR program. 
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Table 2.7: An example of a PCR program 
 Temperature Time Number of cycles 
Initial denaturation 94°C 2 mins 1 cycle 
Denaturation 94°C 20 secs  
     30-40 cycles Annealing 50-65°C 30 secs 
Extension 72°C 60 secs 
Final Extension 72°C 5mins 1 cycle 
 
Annealing temperatures are determined by the Tm of primers used. 
Agarose gel Electrophoresis 
1% Agarose gels were prepared by mixing the exact adequate amount of agarose 
powder in the electrophoresis buffer (1X TAE). The mixture is then heated until 
solution is clear. When solution was cooled to about 60°C, ethidium bromide (0.5 
mg/ml) was then added and the solution poured onto a casting tray containing the 
comb and left to solidify at room temperature. After solidifying, the comb was 
gently removed and the gel placed in the chamber. The 1X TAE buffer was 
poured into the chamber and samples loaded into the gel wells. The 
electrophoresis tank was connected to a power supply and left to run. After a 
successful run the gel was then visualized using a Bio-Rad Gel doc System. 
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Figure 2.2: Schematic representation of RT-PCR showing binding of primer 
(oligoDT) and enzyme (Reverse transcriptase) to synthesize cDNA from mRNA and 
binding of primers to cDNA to produce multiple copies of the gene. 
 
2.2.5 Cloning 
Ligation  
Ligation was performed according to the protocol in the pGEM®-T Easy vector 
system II Catalogue #A1360 including Positive and Negative controls. After all 
reagents were added into the tubes, the reactions were mixed properly and 
incubated overnight at 4°C. Overnight incubation was performed to get the 
maximum number of transformants. 
Transformation of cells 
LB/Ampicillin/IPTG/X-Gal plates were made in preparation for cell 
transformation. Ligation reactions were centrifuged briefly and 2 µl of the 
reaction transferred to sterile 1.5 ml eppendorf tubes on ice. The JM109 High-
Efficiency cells were placed on ice for about 5 mins to thaw. Then 50 µl of the 
cells was added to each of the tubes containing the ligation reaction. After flicking 
     RNA 
Extraction 
     CDNA 
   
Synthesis 
     RT-
PCR 
    
   Agarose gel 
electrophoresis 
OligoDT, RT Specific       
Primers 
Reverse transcription 
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the tubes gently, they were left to incubate in ice for 20 mins. They were then 
removed and heat shocked in a water bath for about 45-50 seconds at 42°C and 
then returned on ice immediately for 2 mins. 950 µl of room temperature LB was 
added and the mixture was left to incubate for 90 mins at 37°C. 100 µl of mixture 
was plated in the LB/ampicillin/IPTG/X-Gal plates previously prepared and 
incubated overnight at 37°C. Colonies were observed and counted manually. 
White colonies were then selected for plasmid DNA purification and also plated 
in fresh new plates to generate and store more clones.   
Plasmid Purification using Qiagen mini purification kit 
A single white colony was cultured overnight 1.5 ml eppendorf tubes and 
centrifuged at 13,000 g for 10 mins. The pellet was then re-suspended in 150 µl of 
buffer 1. 150 µl of buffer 2 was then added and mixture is left to stand at 25°C for 
5 mins. 150 µl of buffer 3 was added and mixture was again gently mixed and left 
to stand at room temperature. The mixture was then centrifuged at 13,000 g for 10 
mins and the supernatant collected. 2.5 volumes of Ethanol Acetate (1:25) was 
then added and mixture is kept at -70°C for 40 mins. After spinning at 13,000 g 
for 10 mins, the pellet was washed with 70% ethanol. Ethanol was then discarded 
and pellet allowed to air dry. 50 µl of Nuclease free water was then added and 
mixture left on ice to dissolve. 
Restriction digestion 
Restriction enzymes were used to digest the plasmid DNA. 0.5- 1 µg of DNA was 
added into a tube on ice followed by 3 µl of the appropriate buffer. 1 µl of the 
enzyme is then added. Nuclease free water was then used to make the volume up 
to 30 µl. 
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Nucleic acid sequencing 
Samples of DNA in the form of PCR products or plasmid clones were sent to 
Inqaba-biotec for sequencing.   
2.2.6 Bioinformatics analysis 
Sequence alignments were done using the DNAMAN programme version 4.03 
(Lynsoft Biosoft). Using the National centre for biotechnology information 
(NCBI) database several blasts were performed to compare the sequences with 
other sequences in the database. 
2.2.7 In vitro Transcription 
In vitro transcription was performed based on the protocol described in the 
Riboprobe® in vitro transcription system catalogue. After adding the required 
reagents into a tube standing at room temperature, the mixture was then incubated 
at 37°C for 1hr. To test the integrity of the sample afterwards, the sample was 
then run on a gel and viewed using the Gel Doc system. After the integrity of the 
sample had been ascertained, the template DNA was then removed based on the 
protocol also described in the Riboprobe® in vitro transcription system catalogue. 
2.2.8 Survival experiment 
Fly treatment and counting  
 800 flies (400 males and 400 females) were placed in different vials of 20’s. Five 
independent experiments was set up. The flies were then exposed to various forms 
of treatments for 3 days and then were transferred to fresh vials containing normal 
yeast for them to recover.  
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The treatment categories include; 
a. 1mM irinotecan 
b. 2.5% methyl pyruvate only 
c. 5% methyl pyruvate only 
d. 10% methyl pyruvate only 
e. Irinotecan + 2.5% methyl pyruvate  
f. Irinotecan + 5% methyl pyruvate  
g. Irinotecan + 10 % methyl pyruvate  
The recovery period lasted for nine days and flies were counted every three days 
in order to ascertain the number of dead and alive flies.  
Kaplan-Meier Survivorship analysis 
The number of dead and living flies was observed at an interval of three days over 
a 12 day period. This raw data was then analysed using the Kaplan- Meier 
survivorship plots. The Kaplan-Meier survival plot is defined as the probability of 
an organism to survive in a given time period, while taking into consideration 
time in short intervals (Goel et al., 2010).  Along the x-axis of the Kaplan-Meier 
plot are horizontal lines that represent the duration of survival at that particular 
interval. This interval is aborted by the occurrence of an event of interest, which 
in our case is death. The vertical lines however, are just to make the plot more 
appealing, although, the distances between the horizontal lines are critical because 
the show the changes in cumulative probability as the plot progresses. 
The formula for calculating the survival probability at a given time is; 
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                         Number of subjects living at the start – Number of subjects dead 
                                          Number of subjects living at the start 
 The plot is a series of declining “staircase-like” horizontal steps. It is widely used 
in the field of medical sciences to estimate the number of patients alive after a 
particular period of time. This estimation is somewhat complicated by the fact that 
not all patients survive through the duration of the experiment as some patients 
drop out or die. The group of patients that die or drop out are called “censored 
observations”. Kaplan-Meier plot is unique in that it is able estimate a survival 
curve that includes censored observations.  
 
 
St = 
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3. Results 
3.1 Introduction 
The aim of this study was to define temporal expression patterns of Dmp53 and 
SNAMA during development and during response to genotoxic stress. We also 
investigated the effects of bypassing the glycolytic pathway by the treatment of 
adult flies with methyl pyruvate. Genetic studies using Drosophila have resulted 
in elucidation of the expression of numerous genes that are observed during 
development and during various kinds of stresses (Arbeitman, 1995). The recent 
discovery of a second smaller Snama isoform (Snama B) has prompted the study 
of their functional importance, particularly their role in DNA damage response.  
3.2 Temporal expression of Snama isoforms. 
In order to show the expression of Snama isoforms during development of the 
Drosophila adult males and females were placed in several fly cages and at 
varying time intervals correlating to various stages of development of Drosophila, 
agar plates were used to collect samples. Temporal expression patterns were 
demonstrated by RT-PCR; Total RNA from adult males and females, embryos, 
larvae and pupae was used. RT-PCR performed in three independent experiments 
showed that both isoforms are differentially expressed during development 
(Figure 3.1). Higher amounts of these isoforms are present in the embryos but 
there is an observed decrease during the adult stages. Snama B seems to be 
decreased at the late embryonic stage (E3), pupal and adult stages. Snama A is 
highly expressed in all stages except in the adult males where it is highly reduced 
and in the E2 embryonic stage where it is undetectable by RT-PCR. 
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Figure 3.1: Expression of Snama isoforms during development. Agarose gel showing 
RT-PCR products on RNA obtained from embryonic stages E1 (0-3hrs), E2 (3-6hrs), E3 
(6-9hrs), Larvae (L), Pupae (P), adult males (Am) and from adult females (Af). Snama A 
and Snama B are both differentially expressed during development, although Snama A is 
undetectable during E2. 
 
3.3 Expression of Snama isoforms, DREF and p53 in untreated and in 
flies undergoing genotoxic stress. 
To induce genotoxic stress, flies were exposed to 1mM irinotecan. A group of 
these flies were left to recover for another three days by transferring them into 
fresh vials. RT-PCR performed in three independent experiments Snama isoforms 
are expressed differentially during treatment (Figure 3.2). Snama B appears to be 
expressed in the same amounts in untreated and treated flies; however slight 
upregulation is observed in treated female flies. Differential expression of Snama 
A is observed in treated and untreated flies. It is upregulated in treated males and 
in virgins and returns to “normal” levels upon recovery. 
Three independent experiments show that p53 is expressed probably as a shorter 
isoform in untreated females whereas during treatment a larger isoform is 
expressed in males and females (Figure 3.2). An upregulation of the level of p53 
is observed during irinotecan treatment.  
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The master cell proliferation gene, DREF (Matsukage et al., 2008), is observed to 
be present in relatively same amounts in the untreated, treated and recovering 
flies.  
RP49 (Ribosomal protein 49), a house keeping gene, is shown to be expressed in 
all categories, however, the gene expression observed during recovery in males 
and female virgins seem to be slightly different in size (Figure 3.2). After several 
repetitions, consistent results were observed and we suggest that a larger isoform 
of RP49 is being expressed under those conditions. However, we are still 
unsuccessful in sequencing after several trials. 
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Figure 3.2: Expression patterns of Snama A, Snama B, DREF, p53 and RP49 in 
untreated, treated  and flies recovering from irinotecan treatment.(a) Agarose gel 
depicting expression of the various genes at various conditions. (b) Densitometry reading 
of 3 independent experiments normalized by RP49 expression. (M=male, F=female, FV= 
virgins).  
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3.4 Survival Analysis of Adult male and female flies when exposed to 
Methyl Pyruvate alone and in combination with Irinotecan. 
Irinotecan, a derivative of camptothecin, targets and inhibits the Topo1 enzyme 
which plays a crucial role in replication of DNA (Hsiang et al., 1985). Irinotecan 
is often used in cancer treatment. In the current study, irinotecan is used to induce 
genotoxic stress.  
Methyl pyruvate provides the end-product of the glycolytic pathway. By treating 
flies with methyl pyruvate, the glycolytic pathway is bypassed. Previous 
experiments conducted on flies show that methyl pyruvate resulted in toxicity at 
the concentration of 10% (Hull and Ntwasa, 2010). In the current study, 800 adult 
flies (400 males and 400 females) were collected, placed in carefully labelled vials 
flies and treated for 3 days with 1mM irinotecan, 10% methyl pyruvate and a 
combined treatment of 1mM irinotecan and 10% methyl pyruvate by 
administration in yeast blobs. Flies were then transferred to fresh vials for 9 days 
to allow for recovery. In adult males and females, the combined treatment (methyl 
pyruvate + irinotecan) and treatment with irinotecan alone had similar survival 
trends (Figure 3.3).  
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Figure 3.3: Survival analysis of male and female adult flies with different 
treatments. In both males (a) and females (b), treatment with 1mM irinotecan and 10% 
methyl pyruvate seems to be toxic to the flies. The plot indicates different groups; co-
treatm (10% methyl pyruvate + 1mM irinotecan), irinoteca (1mM irinotecan), metpyr 
(10% methyl pyruvate only). 
 
Since it is possible that high dosage of methyl pyruvate seems to induce toxicity, 
its concentration was varied to 2.5%, 5% and 10% in another experiment 
a 
b 
41 
 
performed with 800 flies. After five independent experiments, it was observed 
that male flies treated with 2.5% had the highest survival rate, followed by flies 
treated with 5% methyl pyruvate (Figure 3.4a). Flies treated with 2.5% and 5% 
methyl pyruvate seem to have greater survival rates compared to untreated flies. 
At 10% concentration of methyl pyruvate, the flies had the least survival rates just 
as observed by (Hull and Ntwasa, 2010). The best survival trend can be observed 
in flies treated with 2.5% methyl pyruvate only, suggesting that this concentration 
is optimal. The same trend was also observed in the female flies in which flies 
treated with a concentration of 2.5% had the highest survival rate and those 
treated with 10% had the lowest (Figure 3.4b).  
After ascertaining that reducing the concentration of methyl pyruvate given to 
flies somehow increases their survival rates the obvious next step was to also vary 
concentration of methyl pyruvate when combined with irinotecan. After a 3 day 
treatment and a 9 day recovery period in which flies were transferred to fresh 
vials, it was observed that at a combined treatment of 10% methyl pyruvate and 
irinotecan the effects were toxic as observed by (Hull and Ntwasa, 2010) but at  
5% methyl pyruvate concentration the flies seem to have a high survival rate and 
fared even better than untreated flies (Figure 3.5 a,b), suggesting that this 
concentration is optimal when combined with the DNA damaging agent; 
irinotecan.  
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Figure 3.4: Survival analysis of adult male and female flies treated with 
methyl pyruvate alone.  The plot indicates different groups; 10% metpyr (10% methyl 
pyruvate only), 2.5% metpyr (2.5% methyl pyruvate only),  5% metpyr (5% methyl 
pyruvate only) and untreated. 
 
a 
b 
a 
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Figure 3.5: Survival analysis of adult male and female flies when treated with 
methyl pyruvate and irinotecan. The plot indicates different groups; 10%co (10% 
methyl pyruvate + 1mM irinotecan), 2.5%co (2.5% methyl pyruvate + 1mM irinoteca), 
5%co (5% methyl pyruvate + 1mM irinotecan) and untreated. 
 
a 
b 
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3.5 Molecular analysis of the effects of different concentrations of 
methyl pyruvate on the expression of Snama isoforms and the Reaper 
gene (Rpr). 
Survival analysis showed that different methyl pyruvate concentrations affect the 
survival rate of adult flies and this prompted further investigations on the effects 
methyl pyruvate at the molecular level. Adult flies were treated with 2.5% methyl 
pyruvate (the observed optimal concentration) and 10% methyl pyruvate (the 
observed toxic concentration). We observed that Snama A was upregulated during 
10% methyl pyruvate treatment and Snama B upregulated during treatment with 
2.5% methyl pyruvate (Figure 3.6). 
Rpr, an apoptosis inducer, becomes upregulated during treatment with both 2.5% 
and 10% methyl pyruvate. 
RP49, seem not to be expressed during recovery at 2.5% methyl pyruvate 
treatment and this result was consistent after triplicate experiments. Therefore, we 
hypothesize that at those conditions the levels of RNA RP49 might be too low to 
be seen. 
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Figure 3.6: Expression of Snama isoforms and Rpr during treatment with methyl 
pyruvate. (a) Agarose gel depicting expression of the various genes at various 
conditions. (b) Densitometry reading of 3 independent experiments normalized by RP49 
expression. (M= methyl pyruvate) 
  
3.6 Molecular analysis of Adult male and female flies when Methyl 
Pyruvate is combined at different concentration with irinotecan. 
We investigated the effects on the molecular level of a combined treatment of 
irinotecan with 5% methyl pyruvate (optimal concentration) and 10% methyl 
pyruvate (toxic concentration). This investigation was prompted in order to 
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observe what changes occur on the molecular level when these treatments were 
administered. Changes on the expression levels of Snama isoforms and the reaper 
(rpr) gene were observed. 
Three independent experiments showed that the levels of Snama A (the longer 
isoform) were unchanged during the combined treatment with 5% methyl 
pyruvate and also during recovery and that at 10% methyl pyruvate, however, 
Snama B levels seem to slightly increase at 5% methyl pyruvate and decreased 
slightly at 10% (figure 3.7). Significantly, there is an observed slight decrease of 
the levels of the reaper (rpr) gene during recovery at treatment with 5% methyl 
pyruvate. 
RP49 (Ribosomal protein 49) is a house keeping gene in the Drosophila. Figure 
3.7 shows the expression of RP49 in all categories of treatment except in the 
untreated category, even after 3 independent experiments. This might be due to 
the use of male flies (which have been observed to show low RP49 expression 
levels). Furthermore, other transcripts (Snama A, Snama B and Rpr are clearly 
detectable in the same sample confirming the presence of mRNA. 
 
47 
 
 
 
Figure 3.7: Expression of Snama isoforms and rpr during a combined treatment of 
irinotecan and methyl pyruvate. (a) Agarose gel depicting expression of the various 
genes at various conditions. (b) Densitometry reading of 3 independent experiments 
normalized by RP49 expression. (M=methyl pyruvate).  
 
3.7 Survival analysis of p53
-/-
/Snama
-/-
 Adult flies when treated with 
irinotecan and methyl pyruvate. 
We investigated the effects of irinotecan and methyl pyruvate treatments on adult 
flies in which p53 and Snama have been knocked down. Flies were treated for 3 
days and then left to recover for 6 days. During this 9-day period, flies were 
counted every 3 days to ascertain dead and living flies. Untreated mutant flies 
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(untmut) seem to have a higher survival rate compared to untreated wild type flies 
(untwt). Irinotecan-treated mutant flies (irnmut) also survived more than 
irinotecan-treated wild type flies (irnwt). Interestingly, both wild type (irn5mpwt) 
and mutant flies (irn5mpmut) treated with a combination therapy of irinotecan had 
the same survival patterns which was equivalent to those observed in untreated 
wild type flies. The patterns for both irn5mpwt and irn5mpmut are consistent with 
patterns of untreated wildtype flies (untwt) so their patterns lie behind the untwt 
yellow line; therefore they are unseen in this plot (figure 3.8).  
1mM of irinotecan and the optimum concentration of 5% methyl pyruvate were 
used in this experiment. 
 
 
Figure 3.8: Survivorship plots of p53
-/-
/Snama
-/-
  adult flies during treatment. 
Treatment categories include; Untreated mutant flies (untmut), untreated wild type flies 
(untwt), Irinotecan-treated mutant flies (irnmut) irinotecan-treated wild type flies (irnwt), 
mutant flies treated with irinotcan + methyl pyruvate (irn5mpmut), wild type flies treated 
with irinotcan + methyl pyruvate (irn5mpwt). 
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3.8 Cloning of SNAMA isoforms. 
In preparation for in vitro transcription, we cloned both Snama isoforms (A and 
B). Primers for both isoforms were design in such a way as to carefully 
distinguish both isoforms. Primers for Snama A were designed from its 10
th
 exon 
and primers for Snama B were designed from its 3ʹ UTR. These regions are 
unique to the isoforms. After cloning, both samples were linearized using 
restriction enzymes Sal1 for Snama A and AatII for Snama B (Figure 3.9).  
 
Figure 3.9: Linearized Snama A and B. Cloned SNAMA isoforms are about 4kb in 
length. The plasmid used was pGEM-T, which is 3kb in length and the inserts are both 
about 1kb in length. 
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4. Discussion 
 
In this study, the existence of two SNAMA isoforms has been confirmed. It is also 
demonstrated that they are expressed differentially during embryogenesis. 
Furthermore, these isoforms are differentially regulated upon genotoxic stress 
using DNA damaging agents often used during chemotherapy. A potentially 
important aspect of this study is the evidence that when the glycolytic pathway is 
bypassed by the use of methyl pyruvate, beneficial effects can be observed in 
normal cells that are exposed to the chemotherapeutic agents. Another important 
aspect of this study is the observation that indeed SNAMA may have equivalent 
biological roles to Mdm2, the prototypical negative regulator of p53. 
The differential expression of SNAMA isoforms during development suggests 
that they play unique roles. The temporal expression patterns suggest that the 
isoforms are required at different stages during embryogenesis. For example, the 
absence of Snama A during the formation of the cellular blastoderm suggests that 
it is not required at this stage. It has also been observed that the Snama transcripts 
present during the early stages of embryogenesis were deposited by the female 
during oogenesis as early embryos do not transcribe genes. Furthermore, these 
observations suggest that the females overexpress Snama during oogenesis.  
During DNA damage, the differential expression of SNAMA might also suggest 
different roles. It is postulated that SNAMA may function by interacting with p53 
in the same manner as the human (RBBP6) and mouse (PACT) orthologues. It is 
therefore suggested that this interaction somehow negatively regulates p53 levels 
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as it has been observed that higher levels of SNAMA coincide with decreased 
levels of p53. It has also been observed in the current study that the p53
-/-
/Snama
-/- 
and the p53
-/-
/Mdm2
-/- 
phenotypes are similar. This observation further strengthens 
the notion that SNAMA interacts and regulates p53 just like Mdm2 does in 
vertebrates. 
It has also been shown that by bypassing the glycolytic pathway we relieve stress 
during chemotherapy. An increase in survival trend observed when methyl 
pyruvate is administered during chemotherapy may be due to p53-dependent 
control of the glycolytic pathway with consequent apoptosis since p53 interposes 
at different points in the glycolytic pathway. Furthermore, upregulation of Snama 
isoforms during this treatment is significant as evidence suggests that the 
overexpression of SNAMA further reduces elevated p53 levels during 
chemotherapy, thus alleviating apoptotic death. 
4.1 Snama isoforms are differentially expressed throughout 
development.  
Previous studies have shown that SNAMA plays a critical role in embryonic 
development. When Snama was knocked out, lethality of the embryo occurred 
(Mather et al., 2005). Recently, a second isoform of Snama B was discovered 
through bioinformatics analysis performed by Flybase developers (Dos Santos et 
al 2015). This isoform shares the first 7 exons with Snama A (Figure 4.1). 
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Figure 4.1: Schematic representations of Snama A and Snama B showing their exons 
and untranslated regions. The darker regions are the untranslated regions and the lighter 
regions are the translated regions as indicated in the figure. Arrows indicate primers that 
were used in this study to amplify the isoform specifically. 
Source: Hull et. al (submitted) 
 
RT-PCR showed that the 2 isoforms are expressed during development 
differentially. During the early stages of embryogenesis, embryos do not express 
Snama and the gene expressed is maternally derived. However, at the E2 stage (3-
6 hr), when the formation of cellular blastoderm begins, Snama A is undetectable 
by RT-PCR and may not be required. The maternal Snama B persists during this 
period suggesting that it is required for an extended time when compared to 
Snama A. It is significant that Snama A is then expressed zygotically by the 
embryo at the E3 stage (6-9hrs) onwards whereas, Snama B is not. At this stage a 
new wave of cell proliferation is known to occur in the embryo driving 
gastrulation. This implicates Snama A in cellular proliferation which is the major 
process driving this developmental stage. The expression of both isoforms 
differentially during development may also indicate that they play crucial and 
different roles. 
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4.2 SNAMA isoforms are differentially expressed during DNA damage 
When wild type flies are treated with irinotecan, p53 is up-regulated in adult flies 
except in virgins where it is undetectable by RT-PCR. On the other hand, both 
isoforms of SNAMA are expressed differentially (figure 3.2). It is interesting that 
the upregulation of both Snama A, and Snama B are matched with increases in p53 
levels of expression. This may suggest activation of Snama by p53. However, 
there is no evidence, currently, suggesting that p53 can activate transcription of 
Snama. This study shows that during treatment with the DNA damaging agent the 
dominant expression in adults was that of p53 whereas the dormant expression in 
virgins was that of Snama. It is interesting that the expression patterns during 
recovery are similar in males and in virgins and differing with adult females. This 
is important because in a previous study, females seemed to respond differently to 
males with females showing a more severe phenotype (Hull and Ntwasa, 2010).  
4.3 Methyl pyruvate has beneficial effects during chemotherapy 
Irinotecan inhibits the topoisomerase 1 enzyme that regulates unwinding and 
rejoining of DNA strands during DNA replication (Liu et al., 2000). This 
inhibition enables it to kill rapidly dividing cells such as cancer cells. However, 
due to the fact replication is a normal physiological process and due to the fact 
some cells, such as reproductive cells and hair follicle cells also divide rapidly, 
irinotecan is also lethal to normal cells especially the rapidly dividing ones. 
Treatment with a DNA damaging agent induces p53-dependent apoptosis (Morris 
and Geller, 1996). It is well known that treatment with irinotecan is toxic which 
has been confirmed in this study with the low survival rates observed. These 
deaths are likely to be as a result of a p53-dependent apoptosis that is induced by 
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irinotecan. The interposition of p53 at various points in the glycolytic pathway 
enables critical components to be tightly regulated and also results in p53-induced 
apoptosis. Bypassing this pathway might ensure that p53-induced apoptosis is 
avoided. This makes sense since, methyl pyruvate treatment in this study has been 
shown to be beneficial as it increases survival rate during chemotherapy. This 
theory can be supported by the fact that SNAMA is upregulated during treatment 
with methyl pyruvate thus reducing p53-dependent apoptosis. SNAMA, is 
suggested to play a role as a repressor of apoptosis or in negatively regulating an 
apoptosis regulator (Mather et al., 2005). Similarly, the mouse homologue PACT 
was shown to negatively regulate p53 in an Mdm2 dependent manner (Li et al., 
2007). Since p53 levels are increased during DNA damage, it is suggested that the 
upregulation of SNAMA decreases the levels of p53. This stipulation is derived 
from the fact that overexpression of the RBBP6 mouse homologue, PACT, results 
in the Mdm2-dependent degradation of p53 (Li et al., 2007). As this study has 
shown, an increased survival trend is observed with methyl pyruvate treatment; 
this can also be explained by the overexpression of SNAMA which we suggest 
helps decrease p53 levels thus reducing p53-mediated apoptosis. These results 
suggest that methyl pyruvate relieves genotoxic stress and that the clinical 
application of this may help increase the survival of patients undergoing 
chemotherapy. 
4.4 SNAMA probably plays similar roles to Mdm2 
In the current study it has been shown that when the p53 and Snama genes are 
knocked down simultaneously, there is an increase in survival rate. p53 regulates 
apoptosis and this means that without it p53-dependent apoptosis cannot occur. 
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Consequently, cells live longer when this pathway is disrupted by the absence of 
both p53 and Snama. Significantly this phenotype is identical to that of the p53
-/-
/ 
Mdm2
-/-
. The similarity of the p53
-/-
/ Mdm2
-/- 
and p53
-/-
/Snama
-/-
 phenotype is no 
co-incidence as SNAMA and Mdm2 both possess some structural similarities like 
the RING finger domain and the p53 and Rb binding sites. These structural 
features may enable SNAMA to be able to function in the degradation of p53. The 
increase in survival trends observed in p53
-/-
/Mdm2
-/-
 by (Kubbutat et al., 1997) 
and in p53
-/-
/Snama
-/-
 in the current study might be because of the absence of the 
apoptosis inducer p53 and a crucial role played by SNAMA in p53-dependent 
apoptosis. It is therefore tempting to say that SNAMA might function as Mdm2 
does. 
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5. Conclusion 
Contrary to initial beliefs, it is now known that Snama is a broad gene with 
multiple transcipts. The expression of Snama isoforms at different periods in the 
developmental stages hints about their distinctive roles. Also, the expression of 
Snama during genotoxic stress with a possible interaction with p53 makes it a 
possible target for anti cancer drugs.  
The beneficial effects of methyl pyruvate observed in the current study can be 
applied clinically in treatment of cancer patients during chemotherapy. 
6. Future work 
The current study has shown the temporal expression patterns of the isoforms 
during development, however, future studies on the spatial expression of the 
isoforms by in situ hybridization should be carried out. Knowledge about their 
cellular localization may help in elucidating their roles. Also using a technology 
that can produce mutants possessing a single Snama isoforms can also help in 
finding out the unique roles each of the isoforms play. 
It is now known that Snama is expressed during genotoxic stress and this study 
suggests that Snama might play the same role as Mdm2. Future studies regarding 
the interaction between Snama and p53 on how expression of p53 is affected by 
the absence of Snama. This can be done by the knocking down of Snama and 
analysing by Western blot analysis the expression levels of p53. 
It is also now known that by bypassing the glycolytic pathway, stress during 
chemotherapy is relieved probably because of the circumvention of p53-
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dependent apoptosis. In future studies this has to be confirmed by conducting 
apoptotic assays.  
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